Efficacy and long-term safety of a dengue vaccine in regions of endemic disease

A candidate tetravalent dengue vaccine is being assessed in three clinical trials involving more than 35,000 children between the ages of 2 and 16 years in Asian–Pacific and Latin American countries. The researchers report the results of long-term follow-up interim analyses and integrated efficacy analyses.